Anaphylactic reactions and angioedema might occur (patients with «aspirin triad» (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk). Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy. NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including myocardial infarction, stroke, and new onset or worsening of pre-existing hypertension. May cause sodium and fluid retention (caution in heart failure, edema or hypertension). NSAIDs may increase risk of gastrointestinal irritation, ulceration, bleeding, and perforation (caution with history of gastrointestinal disease, concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients). NSAIDs may cause serious skin adverse events (exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis). Use with caution in known or suspected deficiency of CYP2C9 (poor metabolizers may have higher plasma levels due to reduced metabolism). Use with caution in moderate hepatic impairment (avoid use if severe hepatic impairment). Severe hepatic reactions (e.g. fulminant hepatitis, hepatic necrosis, jaundice, liver failure) might occur. May compromise existing renal function (reduction in prostaglandin synthesis may cause a reduction in renal blood flow which may cause renal decompensation; higher risk in impaired renal function, dehydration, heart failure, liver dysfunction, consumption of diuretics and ACEI, and the elderly; long-term NSAID use may result in renal papillary necrosis). When used for juvenile rheumatoid arthritis, celecoxib is not FDA-approved in children <2 years of age or in children <10 kg. Caution in systemic-onset juvenile rheumatoid arthritis (risk for disseminated intravascular coagulation).